Westmead Hospital

Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients (2023) Rouet R, Henry JY, Johansen MD, Sobti M, Balachandran H, Langley DB, Walker GJ, et al. Journal article Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis (2023) May T, Bernardini M, Lheureux S, Aben KK, Bandera EV, Beckmann M, Benitez J, et al. Journal article Endoscopic submucosal dissection techniques and technology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review (2023) Libanio D, Pimentel-Nunes P, Bastiaansen B, Bisschops R, Bourke MJJ, Deprez PHH, Esposito G, et al. Journal article, Review article CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article Pathology Reporting of Gastric Endoscopic Resections: Recommendations From the International Collaboration on Cancer Reporting (2023) Shi C, Webster F, Nagtegaal ID, Bourke MJ, Hong Sm, Kumarasinghe MP, Lam AK, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022 (2022) Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, et al. Journal article KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022) Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Common Genetic Variants Contribute to Risk of Transposition of the Great Arteries (2022) Skoric-Milosavljevic D, Tadros R, Bosada FM, Tessadori F, Van Weerd JH, Woudstra O, Tjong FVY, et al. Journal article